Taltz ® (ixekizumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Taltz Summary of Product Characteristics (SmPC)

Taltz® (ixekizumab): Air bubbles

Air bubbles in the pre-filled pen and the pre-filled syringe are normal. They will not harm the user or affect the dose.

Further information

It is normal to sometimes see an air bubble / air bubbles in the Taltz device. Taltz is injected under the skin (subcutaneous injection). Air bubbles are not a problem in this type of injection. They will not harm the user or affect the dose.1

The air bubble is a normal part of the syringe manufacturing process for Taltz devices.2

The user should not try to remove or expel the air bubble in the device. Removal of the air bubble before injecting is not necessary and not recommended. Doing so can affect the dose.2

References

1. Taltz EU Patient Information Leaflet – Instructions for Use, Utrecht, The Netherlands: Eli Lilly Nederland B.V.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: November 05, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request